76 results about "COPD" patented technology

The invention discloses an EIT-based respiratory muscle force and lung compliance closed-loop evaluation system, which is characterized by comprising a multi-frequency EIT injection / sampling unit, a signal processing unit and a signal processing unit, a pressure measurement and synchronization unit; an FPGA clock synchronization triggering unit; an EIT preprocessing unit; a compressed sensing reconstruction unit; a [delta] Z-Pressure fitting unit is adopted; a feature extraction unit; a control decision unit; and the self-adaptive NMES participates in a trend recording unit. According to the method, advanced technologies such as multi-frequency EIT, compressed sensing reconstruction, machine learning fitting, fuzzy + PID mixed control and federated learning are integrated, a new normal form for closed-loop evaluation and optimization of respiratory muscle force and lung compliance is created, and the method has great clinical value for rehabilitation of diseases such as COPD and neuromuscular respiratory failure.

The invention discloses an intelligent respiratory disease detection system based on lung function measurement indexes, and relates to the technical field of intelligent medical detection. The problems that diagnosis standards are not uniform and depend on experience, primary doctors are prone to missed diagnosis or misdiagnosis due to insufficient experience, and the efficiency of the detection process is low are solved. According to the method, a machine learning model is constructed based on lung function indexes, parameters are optimized through five-fold cross validation, automatic classification of asthma, COPD and ILD / DPLD is achieved, the overall diagnosis accuracy rate reaches 81.3%, the limitation that traditional diagnosis depends on doctor experience is broken through, and the basic medical diagnosis capacity is especially improved. Healthy people are rapidly eliminated through the FVC / FEV1 ratio, invalid calculation is reduced, meanwhile, multi-model weighted fusion is adopted for complex cases, diagnosis robustness is improved, it is ensured that diagnosis results conform to medical logic, the recognition degree of doctors is enhanced, a data basis is provided for clinical research and curative effect tracking, and respiratory disease diagnosis is promoted to develop towards the direction of automation and precision.

The invention relates to the technical field of biological medicine, in particular to a drug screening model construction method based on airway organs, a model and application. The construction method of the drug screening model of the airway organoid comprises the steps of obtaining 2D airway epithelial cells, culturing the airway organoid, establishing an airway organoid inflammation model and / or establishing an airway organoid mucus secretion / goblet cell metaplasia model. Wherein the model is established according to the culture mode of the airway organ in cooperation with a specific stimulant for proliferation and differentiation. Compared with a traditional animal model, the organ-like model is low in cost and short in construction period, can better simulate the pathological process, can realize airway organ-like culture and establishment of an inflammation model and a mucus secretion / goblet cell metaplasia model at the same time, and has a good application prospect in drug detection of asthma and COPD diseases.

A self-regulating oxygen delivery system (100) for COPD, comprising: an oxygen source designed to provide medical oxygen; a sensor module configured to record physiological parameters such as oxygen saturation (SpO2), respiratory rate and pulse rate; a microcontroller-based control unit that is functionally connected to the sensor module and the oxygen source; and an intelligent flow control mechanism controlled by the microcontroller, the system automatically adjusts the oxygen flow in real time based on the recorded physiological parameters to maintain optimal oxygen saturation levels.

This invention provides an application of the peptide Nod-T3 in the preparation of drugs for treating lung diseases. The Nod-T3 peptide is derived from human protein and has a significant inhibitory effect on chronic lung inflammation and fibrosis caused by smoking. It can be used to treat COPD and other smoking-related lung diseases. It also has high biocompatibility and low toxicity, and has the potential and development value to become a new type of peptide drug.

IL33 antagonists, alone or in combination with IL-4R antagonists, can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyps in subjects having one or more risk alleles in intronic IL1RL1 variant rs1420101, in IL33 variant rs1342326, in both, or in variants in linkage disequilibrium therewith.

To provide methods for treating or preventing COPD and related conditions.SOLUTION: A disclosed method comprises a step of administering a therapeutic composition comprising an interleukin-33 (IL-33) such as an anti-IL-33 antibody or antigen binding fragment thereof to a subject in need thereof.SELECTED DRAWING: None

The utility model discloses a device for constructing a COPD fruit fly model by adopting smoke exposure, which is characterized in that a sealing mechanism is arranged between a box body and a box cover, the box body is transparent, a fruit fly placing mechanism is arranged in the box body, a smoke inlet pipe is arranged on the side wall of the box body in a penetrating manner, and a smoke pushing mechanism is arranged on the smoke inlet pipe; one end of a connecting pipe of the cigarette pushing mechanism is communicated with a cigarette pushing barrel, the other end of the connecting pipe is provided with a double-layer sleeve body, the double-layer sleeve body comprises an outer sleeve body and an inner sleeve arranged in the outer sleeve body, the outer sleeve body and the inner sleeve are arranged on the periphery and the inner wall of a cigarette inlet pipe in a sleeved mode respectively, the outer sleeve body is connected with the outer wall of the connecting pipe, and the inner sleeve is communicated with the connecting pipe. The smoke pushing cylinder comprises a needle cylinder and a piston arranged in the needle cylinder in a penetrating mode. According to the smoke exposure device, smoke can enter the smoke box through the smoke inlet conveniently for smoke exposure, the smoke exposure device can be used for construction of a COPD disease model, drug treatment and drug effect evaluation, and technical support is provided for construction of the COPD model in a smoke exposure mode.

The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and / or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and / or prophylaxis of diseases, especially for treatment and / or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.

The invention discloses an intelligent early warning system for acute exacerbation of COPD home NPPV, which belongs to the technical field of medical treatment and comprises a real-time multi-dimensional physiological data time sequence acquisition module, a COPD acute exacerbation prediction model and an early warning module. The real-time multi-dimensional physiological data time sequence acquisition module is used for acquiring a real-time multi-dimensional physiological data time sequence of a patient; the COPD acute exacerbation prediction model is used for outputting the probability that the patient has COPD acute exacerbation in the future according to the input real-time multi-dimensional physiological data time sequence; and the early warning module is used for performing early warning when the probability of acute exacerbation of COPD of the patient in the future is greater than a preset threshold value. According to the method, the prediction precision of whether COPD acute exacerbation occurs in the future can be improved, and early discovery and early treatment are realized.

The present invention generally relates to pharmaceutical composition comprising a LABA agent, optionally in combination with other active ingredients, a mixture of an acid and a chelating agent, a propellant and a co-solvent. The invention also provides a pharmaceutical composition for the treatment of respiratory diseases, such as asthma and COPD.

The present invention relates to novel 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as potent inhibitors of transforming growth factor-beta receptor I (also known as activin receptor-like kinase 5) (TGFβRI) / ALK5. Other objects of the present invention are to provide processes for preparing these compounds; pharmaceutical compositions comprising an effective amount of these compounds; the use of said compounds for the preparation of a medicament for the treatment of pathological conditions or diseases which can be ameliorated by the inhibition of transforming growth factor-beta receptor I (TGFβRI) / ALK5, such as respiratory diseases, including idiopathic pulmonary fibrosis, asthma, COPD and lung cancer and skin and ocular fibrotic disorders.

The invention relates to the technical field of medical image processing, and discloses a chronic obstructive pulmonary emphysema distribution quantitative method and system based on multi-scale segmentation, and the method comprises the steps: carrying out the anisotropic diffusion filtering noise reduction of a chest CT image; segmenting a lung field and removing a blood vessel bronchial structure by adopting a region growing algorithm; multi-scale image representation is constructed based on a Gaussian pyramid, an emphysema candidate area is identified in a coarse scale layer, and a boundary is accurately drawn by adopting a self-adaptive threshold value in a fine scale layer; extracting local texture features to distinguish the lobular central emphysema and the total lobular emphysema; dividing severity levels according to spatial aggregation characteristics and density gradient distribution, and calculating an air swelling volume ratio and a distribution heterogeneity index; the three-dimensional pseudo-color volume is used for drawing visualization, a structured quantitative report is generated, accurate segmentation and subtype classification of the emphysema area are achieved, and comprehensive quantitative analysis indexes are provided.

This invention relates to catheter and handle assemblies for tissue treatment. More specifically, the invention relates to a catheter assembly having an elongated shaft, an ablation component coupled to one end of the shaft, and a handle coupled to the other end of the shaft. The handle facilitates axial and circumferential positioning of the ablation component via the shaft in an airway, tubing, or blood vessel for tissue treatment. Embodiments include using the handle during treatment of lung diseases such as COPD and asthma to facilitate axial and circumferential positioning of the shaft and ablation component through and independently of the working channel of a bronchoscope.

Pulmonary treatment devices, systems and methods of use are provided which take into account the vast tissue damage of advanced COPD sufferers and provide treatments designed specifically to treat the particularly compromised lung tissues that are present in these patients. These treatments reduce trapped air volume, tension lung tissue and enhance lung elastic recoil. In particular, a variety of embodiments of invertible pulmonary treatment devices are provided. The devices are comprised of a shape memory material wherein the devices are able to be expanded under tension, and then are able to recoil back toward an original relaxed or resting shape. In these embodiments, a portion of the device is invertible. Thus, each device is able to store energy at least in the inversion, wherein the energy is utilized to continually tension the lung as the device relaxes toward its original shape.

The present disclosure describes a sulfate salt form of vapendavir and a pharmaceutical composition containing the same. Methods of treating a subject having a respiratory enterovirus by administering to the subject a pharmaceutical composition including a therapeutically effective amount of the vapendavir sulfate are also described, wherein the subject may or may not also have COPD or asthma.

Provided herein are compositions and methods for treating and preventing lung disease. In particular, provided herein are SP-A peptides and uses thereof in the treatment and prevention of lung disease (e.g., asthma or COPD).

A method to assess the disease status, determine the mean / average control of the disease and monitor the compliance to treatment over a period of time of a respiratory disease, comprising of predicting the degree of airway inflammation and disease activity by measuring the inflammatory markers, evaluating the mucosal integrity / damage by measuring the moisture levels of the exhaled air, evaluating the breathing function and obstruction by measuring the FEV1 value, and evaluating the symptom control by determining the COPD Score.

This invention relates to an antisense oligonucleotide targeting the interleukin-4 receptor and its applications. The antisense oligonucleotide (ASO) molecule is 16-22 bases in length and specifically pairs with a specific region of the target gene (interleukin-4 receptor). The ASO is used to treat diseases related to IL-4Rα, including but not limited to asthma (including eosinophilic types), atopic dermatitis, eosinophilic esophagitis, sinusitis, nasal polyps, nodular prurigo, urticaria, COPD, bullous pemphigoid, pruritus, and gastritis.

1. The name of the design product: respiratory training device (COPD care). 2. The use of the design product: for respiratory rehabilitation training, improve respiratory function. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective drawing.

The present disclosure relates to the treatment of asthma and COPD with pulsed electric field ablation and precision drug delivery. Methods, systems, and devices related to pulsed field ablation treatment of respiratory diseases and deformities are disclosed. In some examples, ablation catheters and methods of use are disclosed that can include an ablation catheter comprising a proximal shaft comprising an inflatable stent, a control knob, a distal shaft comprising a distal tip disposed near a distal end of the distal shaft. Systems, methods, and devices can also incorporate a control knob disposed near the proximal shaft and the distal shaft. The ablation catheters described herein can include one or more electrodes, and both the proximal shaft and the distal shaft can include at least one lumen for the one or more electrodes to pass therethrough.

The present invention relates a process for preparing a compound of Formula XX wherein: R1 is hydrogen, optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, alkoxy, aryloxy, alkenyloxy or alkynyloxy; R2 is an N-containign heterocyclyl or heteroaryl; and Q is optionally substitued aryl or heteroaryl. Furthermore a compound of the present invention are useful in the treamtment of various inflammatory, autoimmune and allergic diseases, such as method of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoartluitis, psoriatic arthritis, psoriasis, pulmonary fibrosis, wound healing disorders, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by the overexpression and over-activation of a matrix metalloproteinase using the compound.

Pulmonary treatment devices, systems and methods of use are provided which take into account the vast tissue damage of advanced COPD sufferers and provide treatments designed specifically to treat the particularly compromised lung tissues that are present in these patients. These treatments reduce trapped air volume, tension lung tissue and enhance lung elastic recoil. In particular, a variety of embodiments of invertible pulmonary treatment devices are provided. The devices are comprised of a shape memory material wherein the devices are able to be expanded under tension, and then are able to recoil back toward an original relaxed or resting shape. In these embodiments, a portion of the device is invertible. Thus, each device is able to store energy at least in the inversion, wherein the energy is utilized to continually tension the lung as the device relaxes toward its original shape.

The present disclosure describes a sulfate salt form of vapendavir and a pharmaceutical composition containing the same. Methods of treating a subject having a respiratory enterovirus by administering to the subject a pharmaceutical composition including a therapeutically effective amount of the vapendavir sulfate are also described, wherein the subject may or may not also have COPD or asthma.

This invention belongs to the field of biomedical technology and relates to a composition based on plant essential oils or active ingredients and its application in the preparation of drugs for the prevention and treatment of pulmonary edema. It comprises at least three plant essential oils or active ingredients; said plant essential oils or active ingredients have agonistic activity against aquaporins and agonistic activity against sodium-potassium ATPase. The composition and its special formulation provided by this invention not only have good preventive and therapeutic effects on pulmonary edema, but can also be applied to the prevention and treatment of related lung diseases such as hypersputum secretion, acute lung injury, acute respiratory distress syndrome, pulmonary fibrosis, and COPD.

The invention relates to a catheter and handle assembly for treating tissue. More specifically, the present invention relates to catheter assemblies having an elongate shaft, an ablation assembly coupled to one end of the shaft, and a handle coupled to the other end of the shaft. The handle facilitates axial and circumferential positioning of the ablation assembly through the shaft in the airway, conduit or vessel for treatment of tissue. Embodiments include the use of a handle to facilitate axial and circumferential positioning of the shaft and ablation assembly through and independent of the working channel of the bronchoscope during the treatment of pulmonary diseases such as COPD and asthma.

The present disclosure is a telescopic endobronchial stem cell cultivation catheter that comprises a segment catheter (1), a terminal catheter (2), and a respiratory catheter (3) ensuring that ensures the prevention of the progression of COPD and provides early treatment before it progresses to advanced stages, allows the increase of the number of reduced lung parenchyma by means of its inoculation feature in advanced COPD stages, provides the removal of metaplastic cells in the bronchial walls in the application area with the rhythmic inflation-deflation movement by means of the balloons (1.2, 2.2, 3.2) and reduces the risk of future cancer formation, and increases respiratory ventilation by expanding narrowed terminal bronchioles (11) and increasing air flow to the respiratory bronchioles (12).

The present application relates to the field of medical imaging technology, specifically to a COPD early warning method and system based on chest CT parameters, comprising the following steps: based on chest CT image data, extracting pixel data of lung lobe anatomical region, segmenting airway tree structure, identifying bronchial wall boundary, screening gradient change points, and generating airway wall boundary point set. In the present application, by refining the lung lobe anatomical region, segmenting the airway tree structure, accurately positioning the bronchial wall boundary, calculating the airway wall thickness, correcting abnormal fluctuations, improving the stability of the thickness parameter, using the thickness parameter to calculate the airflow passage cross-sectional area, analyzing the lung lobe ventilation volume and ventilation change, quantifying the lung ventilation imbalance degree, screening the ventilation restricted area, analyzing the relationship between the wall thickness and the ventilation change rate, extracting the abnormal growth area, marking the ventilation restriction severity, setting the early warning threshold, calculating the abnormal index mean value, marking the risk area, enhancing the ventilation abnormality recognition hierarchy, and improving the early warning ability of COPD.

Described herein are methods of treating cystic fibrosis, asthma, COPD, and other airway related diseases in a patient by administering a therapeutically effective amount of a specific enantiomer, R-vanzacaftor or a pharmaceutically acceptable salt thereof, to the patient.